Correction

Correction: High-Throughput Screening Identifies Idarubicin as a Preferential Inhibitor of Smooth Muscle versus Endothelial Cell Proliferation

The *PLOS ONE* Staff

The following information is missing from the Funding section: This work was supported by University of Wisconsin ICTR-Clinical and Type 1 Translational Research Pilot Program (UL1TR000427 to K.C.K.). This funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Reference

1. Goel SA, Guo L-W, Wang B, Guo S, Roenneburg D, et al. (2014) High-Throughput Screening Identifies Idarubicin as a Preferential Inhibitor of Smooth Muscle versus Endothelial Cell Proliferation. PLoS ONE 9(2): e89349. doi:10.1371/journal.pone.0089349

Citation: The *PLOS ONE* Staff (2014) Correction: High-Throughput Screening Identifies Idarubicin as a Preferential Inhibitor of Smooth Muscle versus Endothelial Cell Proliferation. PLoS ONE 9(10): e110098. doi:10.1371/journal.pone.0110098

Published: October 1, 2014

Copyright: © 2014 The *PLOS ONE* Staff. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.